Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 6, 2026Reported sale · Form 4Fred Aslan, Chief Executive Officer · $168.9KOpen the filing ↗
- Oct 6, 2026Notice of sale · Form 144FRED ASLAN · Director, Officer · $245.7KOpen the filing ↗
- Oct 5, 2026Reported sale · Form 4Fred Aslan, Chief Executive Officer · $421.8KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record20614 flagged findings
Reported transactions (Form 4)80since Dec 12, 2025 · and 39 other holdings
Corporate events (8-K)8since Oct 22, 2024
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-08share offering or dilution eventrecentOpen filing ↗“…the underwriting discount and commissions and estimated offering expenses payable by the Company. The closing of the offering is…”
- 2026-05-08share offering or dilution eventrecentOpen filing ↗“…ownership of shares of common stock or securities convertible into shares of common stock, regardless of whether any such transaction…”
+1 more passage from the same document
- “…convertible into shares of common stock, or cause to be filed a registration statement, prospectus or prospectus supplement (or an…”
- 2026-05-08capital return (buybacks/dividends)recentOpen filing ↗“…cover withholding tax obligations in connection with such exercise, vesting, exchange or settlement) pursuant to an employee benefit…”
+1 more passage from the same document
- “…prospectus and any applicable prospectus supplement, our board of directors will determine the designations, voting powers,…”
- 2026-05-08share offering or dilution eventrecentOpen filing ↗“…shares of common stock, par value of $ 0.0001 per share, and 10,000,000 shares of preferred stock, par value of $ 0.0001 per share.…”
+1 more passage from the same document
- “…plans, we expect our existing cash, cash equivalents and investments will be sufficient to fund our planned operating expenses and…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 206)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 7, 26Form 4 ↗Insider transaction
- Oct 6, 26Form 144 ↗Notice of proposed sale
Insider transaction · 17 Form 4 filingsshow all 17hide
- Oct 6, 26Form 4 ↗Insider transaction
- Oct 6, 26Form 4 ↗Insider transaction
- Oct 6, 26Form 4 ↗Insider transaction
- Oct 6, 26Form 4 ↗Insider transaction
- Sep 15, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 14, 26Form 4 ↗Insider transaction
- Sep 11, 26Form 4 ↗Insider transaction
- Sep 11, 26Form 4 ↗Insider transaction
- Sep 11, 26Form 4 ↗Insider transaction
- Sep 11, 26Form 4 ↗Insider transaction
- Sep 11, 268-K ↗Current report · A senior executive left or was appointed
- Sep 9, 26Form 4 ↗Insider transaction
- Sep 8, 26Form 144 ↗Notice of proposed sale
206 filings on record, the oldest from Apr 8, 21.
Listing the 25 most recent filings of the 206 on record.
8
8 senior executive changes2024 – 2026show all 8hide
- Sep 11, 26A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- May 19, 26A senior executive left or was appointed8-K 5.02 ↗
- Feb 24, 26A senior executive left or was appointed8-K 5.02 ↗
- Feb 19, 26A senior executive left or was appointed8-K 5.02 ↗
- Dec 12, 25A senior executive left or was appointed8-K 5.02 ↗
- Jun 25, 25A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jan 29, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Oct 22, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13D: stake and stated purpose
Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.
- RA Capital Management, L.P.37.9%Jul 22, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 2 earlier filings
- GC Corp12.3%May 11, 26SCHEDULE 13D/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- VIKING GLOBAL INVESTORS LP5.4%May 11, 26SCHEDULE 13G ↗10 co-filers on this document — the figure is the largest single stake, not their sum.
- venBio Global Strategic Fund III, L.P.4.9%Mar 31, 25SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
- Andrew J. Schwab4.8%Jun 30, 26SCHEDULE 13G/A ↗6 co-filers on this document — the figure is the largest single stake, not their sum.
- Venrock Healthcare Capital Partners III, L.P.4.2%Jun 30, 26SCHEDULE 13G/A ↗7 co-filers on this document — the figure is the largest single stake, not their sum.
- BlackRock, Inc.2.0%Jun 30, 25SCHEDULE 13G/A ↗1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 6, FRED ASLAN filed notice of intent to sell up to $246K. That is about 0.07% of shares outstanding. It is filed under a scheduled plan (10b5-1), arranged in advance.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $169K on Oct 6, per their Form 4. That is 68% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+3 more recent notices · 3 with a later sale
- Oct 6, 26Sell$169KFred AslanChief Executive Officer↗
- Oct 5, 26Sell$422KFred AslanChief Executive Officer↗
- Oct 5, 26Sell$8KSubhashis BanerjeeChief Medical Officer↗
- Oct 5, 26Sell$57KJennifer BushCOO, CLO, Compliance Officer↗
- Oct 5, 26Sell$71KChristopher HoranChief Tech Operations Officer↗
- Sep 8, 26Sell$256KFred AslanChief Executive Officer↗
- Sep 3, 26Sell$690KFred AslanChief Executive Officer↗
- Sep 3, 26Sell$12KSubhashis BanerjeeChief Medical Officer↗
- Sep 3, 26Sell$94KJennifer BushCOO, CLO, Compliance Officer↗
- Sep 3, 26Sell$116KChristopher HoranChief Tech Operations Officer↗
- Aug 27, 26Sell$99KSubhashis BanerjeeChief Medical Officer↗
- Aug 18, 26Sell$5KSubhashis BanerjeeChief Medical Officer↗
There are 20 more transactions in this stretch.
Stock compensation, tax and giftsshow the 8 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Sep 15, 26Compensationamount n/aFred AslanChief Executive Officer↗
- Sep 10, 26Compensationamount n/aFred AslanChief Executive Officer↗
- Sep 9, 26Compensationamount n/aSubhashis BanerjeeChief Medical Officer↗
- Sep 9, 26Compensationamount n/aJennifer BushCOO, CLO, Compliance Officer↗
- Sep 9, 26Compensationamount n/aChristopher HoranChief Tech Operations Officer↗
- Sep 9, 26Compensationamount n/aGines Diego MirallesPresident & Head of R&D↗
- Aug 27, 26Compensation$10KSubhashis BanerjeeChief Medical Officer↗
- Aug 18, 26Compensation$824Subhashis BanerjeeChief Medical Officer↗
The full record holds 126 transactions and goes back to Jul 18, 24.
Its sector and its market
Artiva Biotherapeutics Inc. among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Artiva Biotherapeutics Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Artiva Biotherapeutics Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- Series with incidents in the period; the chart shows what could be kept.
- SEC records
- 206 documents on file, from Apr 8, 2021 to Oct 7, 2026.
- Company description
- No description available.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.